Skip to Content

Newsroom

Cancer Drug Shortage Is Costing Lives

Cancer Newsline - 04/04/2011

Acute myelogenous leukemia (AML) is a fast-progressing cancer that typically takes a patient’s life within two to three months if not treated quickly and properly. Cytarabine is the only known drug to affectively treat AML, having a survival rate of 40% to 50%. Without cytarabine, the survival rate is 0%. The number of drugs, including those used to treat cancer, that are in short supply within the United States has tripled since 2005. Hagop Kantarjian, M.D., chair of the Department of Leukemia at MD Anderson Cancer Center, speaks out on this topic.

Guest: Hagop Kantarjian, M.D.


© 2014 The University of Texas MD Anderson Cancer Center